B.1.1.7 variant linked to 55% higher mortality compared to other strains of SARS-CoV-2
B.1.1.7 variant linked to 55% higher mortality compared to other strains of SARS-CoV-2 15 March 2021 London School of Hygiene & Tropical Medicine London School of Hygiene & Tropical Medicine https://lshtm.ac.uk/themes/custom/lshtm/images/lshtm-logo-black.png
New variant threatens to cancel out the improvements in COVID-19 treatment Share
The B.1.1.7 variant is very likely to cause more severe illness than pre-existing SARS-CoV-2 variants, according to new research published in
The research team at the London School of Hygiene & Tropical Medicine analysed the results of more than two million COVID-19 community tests in England between November 2020 and February 2021.
The Oxford/AstraZeneca vaccine has not had an easy few months. First, trial results suggested it was not as effective as other jabs. Then several European countries ruled it was unsuitable for over-65s.
In the latest twist, Ireland, the Netherlands, Germany, Denmark, Iceland, Bulgaria, France, Italy and Norway have all halted their AstraZeneca rollouts over fears that the jab is causing blood clots.
So should people be worried if they have been immunised with the British vaccine? The numbers suggest not.
According to the charity Thrombosis UK, up to one in 1,000 people each year will experience a dangerous blood clot in a vein, known as a venous thrombosis. That means about 66,000 people in Britain might be expected to suffer a blood clot annually – or 1,269 a week.
Should I be concerned about the Oxford/AstraZeneca vaccine? pressandjournal.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressandjournal.co.uk Daily Mail and Mail on Sunday newspapers.